Metabolic Brain Disease

, Volume 24, Issue 1, pp 27–53

The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression

  • Michael Maes
  • Raz Yirmyia
  • Jens Noraberg
  • Stefan Brene
  • Joe Hibbeln
  • Giulia Perini
  • Marta Kubera
  • Petr Bob
  • Bernard Lerer
  • Mario Maj
Original Paper

Abstract

Despite extensive research, the current theories on serotonergic dysfunctions and cortisol hypersecretion do not provide sufficient explanations for the nature of depression. Rational treatments aimed at causal factors of depression are not available yet. With the currently available antidepressant drugs, which mainly target serotonin, less than two thirds of depressed patients achieve remission. There is now evidence that inflammatory and neurodegenerative (I&ND) processes play an important role in depression and that enhanced neurodegeneration in depression may–at least partly–be caused by inflammatory processes. Multiple inflammatory-cytokines, oxygen radical damage, tryptophan catabolites–and neurodegenerative biomarkers have been established in patients with depression and these findings are corroborated by animal models of depression. A number of vulnerability factors may predispose towards depression by enhancing inflammatory reactions, e.g. lower peptidase activities (dipeptidyl-peptidase IV, DPP IV), lower omega-3 polyunsaturated levels and an increased gut permeability (leaky gut). The cytokine hypothesis considers that external, e.g. psychosocial stressors, and internal stressors, e.g. organic inflammatory disorders or conditions, such as the postpartum period, may trigger depression via inflammatory processes. Most if not all antidepressants have specific anti-inflammatory effects, while restoration of decreased neurogenesis, which may be induced by inflammatory processes, may be related to the therapeutic efficacy of antidepressant treatments. Future research to disentangle the complex etiology of depression calls for a powerful paradigm shift, i.e. by means of a high throughput-high quality screening, including functional genetics and genotyping microarrays; established and novel animal and ex vivo–in vitro models for depression, such as new transgenic mouse models and endophenotype-based animal models, specific cell lines, in vivo and ex vivo electroporation, and organotypic brain slice culture models. This screening will allow to: 1) discover new I&ND biomarkers, both at the level of gene expression and the phenotype; and elucidate the underlying molecular I&ND pathways causing depression; and 2) identify new therapeutic targets in the I&ND pathways; develop new anti-I&ND drugs for these targets; select existing anti-I&ND drugs or substances that could augment the efficacy of antidepressants; and predict therapeutic response by genetic I&ND profiles.

Keywords

Depression Inflammation Cytokines Neurodegeneration Oxidative stress Nitrosative stress Tryptophan Serotonin IDO. 

References

  1. Amodio P, De Toni EN, Cavalletto L, Mapelli D, Bernardinello E, Del Piccolo F, Bergamelli C, Costanzo R, Bergamaschi F, Poma SZ, Chemello L, Gatta A, Perini G (2005) Mood, cognition and EEG changes during interferon (αIFN) treatment for chronic hepatitis C. J. Affect. Disord. 84(1):93–98PubMedGoogle Scholar
  2. Angelucci F, Brene S, Mathe AA (2005) BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 10(4):345–352PubMedGoogle Scholar
  3. Anisman H, Kokkinidis L, Merali Z (2002) Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Beh. Immun. 16(5):544–556 ReviewGoogle Scholar
  4. Anisman H, Merali Z, Poulter MO, Hayley S (2005) Cytokines as a precipitant of depressive illness: animal and human studies. Curr. Pharm. Design 11(8):963–972Google Scholar
  5. Anisman H, Poulter MO, Gandhi R, Merali Z, Hayley S (2007) Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. J. Neuroimmunol. 186(1–2):45–53PubMedGoogle Scholar
  6. Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E, Lehtimaki T (2007) Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J. Neural. Transm. 114(8):1065–1068PubMedGoogle Scholar
  7. Babcock TA, Carlin JM (2000) Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 12(6):588–594PubMedGoogle Scholar
  8. Banerjee A, Jain G, Grover S, Singh J (2007) Mania associated with interferon. J. Postgraduate Med. 53(2):150Google Scholar
  9. Bazan NG, Marcheselli VL, Cole-Edwards K (2005) Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann. NY Acad. Sci. 1053:137–147 ReviewPubMedGoogle Scholar
  10. Beck RD Jr., Wasserfull C, Ha GK, Cushman JD, Huang Z, Atkinson MA, Petitto JM (2005) Changes in hippocampal IL-15, related cytokines, and neurogenesis in IL-2 deficient mice. Brain Res. 1041:223–230PubMedGoogle Scholar
  11. Beltz BS, Sandeman DC (2003) Regulation of life-long neurogenesis in the decapod crustacean brain. Arth. Struct. Dev. 32:39–60Google Scholar
  12. Beltz BS, Tlusty MF, Benton JL, Sandeman DC (2007) Omega-3 fatty acids upregulate adult neurogenesis. Neurosci. Lett. 145(2):154–158Google Scholar
  13. Benazzi F (2007a) Bipolar II Disorder : Epidemiology, Diagnosis and Management. CNS Drugs. 21(9):727–740PubMedGoogle Scholar
  14. Benazzi F (2007b) Is there a continuity between bipolar and depressive disorders? Psychoth. Psychosom. 76(2):70–76Google Scholar
  15. Berlim MT, Turecki G (2007) Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can. J. Psychiatry 52(1):46–54PubMedGoogle Scholar
  16. Bjornebekk A, Mathe AA, Brene S (2005) The antidepressant effect of running is associated with increased hippocampal cell proliferation. Int. J. Neuropsychopharmacol. 8(3):357–368PubMedGoogle Scholar
  17. Bjørnebekk A, Mathé AA, Gruber SH, Brené S (2007) Social isolation increases number of newly proliferated cells in hippocampus in female flinders sensitive line rats. Hippocampus. 17(12):1193–1120PubMedGoogle Scholar
  18. Bjørnebekk A, Mathé AA, Gruber SH, Brené S (2008) Housing conditions modulate escitalopram effects on antidepressive-like behaviour and brain neurochemistry. Int. J. Neuropsychopharmacol. 23:1–13Google Scholar
  19. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer HY, Maes M (2001) Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 105(1–2):45–55PubMedGoogle Scholar
  20. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M (2002a) Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J. Affect. Disord. 72(3):237–241PubMedGoogle Scholar
  21. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M (2002b) Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 22(1):86–90PubMedGoogle Scholar
  22. Bremner JD, Narayan M (1998) The effects of stress on memory and the hippocampus throughout the life cycle: implications for childhood development and aging. Developm. Psychopathol. 10(4):871–885Google Scholar
  23. Brown ES, Rush AJ, McEwen BS (1999) Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacol. 21(4):474–484Google Scholar
  24. Brown ES, J Woolston D, Frol A, Bobadilla L, Khan DA, Hanczyc M, Rush AJ, Fleckenstein J, Babcock E, Cullum CM (2004) Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol. Psychiatry 55(5):538–545PubMedGoogle Scholar
  25. Bukalo O, Fentrop N, Lee AY, Salmen B, Law JW, Wotjak CT, Schweizer M, Dityatev A, Schachner M (2004) Conditional ablation of the neural cell adhesion molecule reduces precision of spatial learning, long-term potentiation, and depression in the CA1 subfield of mouse hippocampus. J. Neurosci. 24:1565–1577PubMedGoogle Scholar
  26. Campbell S, MacQueen G (2006) An update on regional brain volume differences associated with mood disorders. Curr. Opin. Psychiatry 19(1):25–33PubMedGoogle Scholar
  27. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH (2003) Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry 54(9):906–914PubMedGoogle Scholar
  28. Carter CJ (2007) Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. Neurochem. Int. 50(3):461–490PubMedGoogle Scholar
  29. Castanon N, Bluthé RM, Dantzer R (2001) Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacol. 154(1):50–60Google Scholar
  30. Chavez AM, Menconi MJ, Hodin RA, Fink MP (1999) Cytokine-induced intestinal epithelial hyperpermeability: role of nitric oxide. Crit. Care Med. 27(10):2246–2251PubMedGoogle Scholar
  31. Checa N, Canals JM, Alberch J (2000) Developmental regulation of BDNF and NT-3 expression by quinolinic acid in the striatum and its main connections. Exp. Neurology 165(1):118–124Google Scholar
  32. Chung KK, Dawson TM, Dawson VL (2005) Nitric oxide, S-nitrosylation and neurodegeneration. Cell Mol. Biol. (Noisy-le-grand) 51(3):247–254 ReviewGoogle Scholar
  33. Clark E, Hoare C, Tanianis-Hughes J, Carlson GL, Warhurst G (2005) Interferon gamma induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterol. 128(5):1258–1267Google Scholar
  34. Contestabile A (2001) Oxidative stress in neurodegeneration: mechanisms and therapeutic perspectives. Curr. Topics Med. Chemistry 1(6):553–568 ReviewGoogle Scholar
  35. Coti Bertrand P, O'Kusky JR, Innis SM (2006) Maternal dietary (n-3) fatty acid deficiency alters neurogenesis in the embryonic rat brain. J. Nutr. 136(6):1570–1575PubMedGoogle Scholar
  36. Cowen PJ (2002) Cortisol, serotonin and depression: all stressed out? Brit. J. Psychiatry 180:99–100Google Scholar
  37. de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, van den Wijngaard RM, Boeckxstaens GE (2005) Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nature Immunol 6(8):844–851Google Scholar
  38. Dinan T (2001) Novel approaches to the treatment of depression by modulating the hypothalamic—pituitary—adrenal axis. Hum. Psychopharmacol. 16(1):89–93PubMedGoogle Scholar
  39. Duman RS (2002) Pathophysiology of depression: the concept of synaptic plasticity. Eur. Psychiatry 17(Suppl 3):306–310PubMedGoogle Scholar
  40. Duman RS (2004) Depression: a case of neuronal life and death? Biol. Psychiatry 56(3):140–145PubMedGoogle Scholar
  41. Ehninger D, Kempermann G (2006) Paradoxical effects of learning the Morris water maze on adult hippocampal neurogenesis in mice may be explained by a combination of stress and physical activity. Genes Brain Beh. 5(1):29–39Google Scholar
  42. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O (2003) Inflammation is detrimental for neurogenesis in adult brain. Proc. Nat. Acad. Sci. USA. 100(23):13632–13637PubMedGoogle Scholar
  43. el-Defrawy SR, Boegman RJ, Jhamandas K, Beninger RJ (1986) The neurotoxic actions of quinolinic acid in the central nervous system. Can. J. Physiol. Pharmacol. 64(3):369–375PubMedGoogle Scholar
  44. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG (2006) Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol. Med. 36(1):37–43PubMedGoogle Scholar
  45. Forlenza MJ, Miller GE (2006) Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosomatic Med. 68(1):1–7Google Scholar
  46. Fuchs E, Czeh B, Kole MH, Michaelis T, Lucassen PJ (2004) Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur. Neuropsychopharmacol. 5(14 Suppl):S481–490Google Scholar
  47. Garthwaite G, Garthwaite J (1987) Quinolinate mimics neurotoxic actions of N-methyl-D-aspartate in rat cerebellar slices. Neurosci. Lett. 79(1–2):35–39PubMedGoogle Scholar
  48. Gould E, McEwen BS, Tanapat P, Galea LA, Fuchs E (1997) Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation.J. Neurosci. 17(7):2492–2498Google Scholar
  49. Guillemin GJ, Smith DG, Kerr SJ, Smythe GA, Kapoor V, Armati PJ, Brew BJ (2000) Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Report 5(2–3):108–111PubMedGoogle Scholar
  50. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, Yirmiya R (2008) Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13(7):717–728PubMedGoogle Scholar
  51. Groves JO (2007) Is it time to reassess the BDNF hypothesis of depression? Mol. Psychiatry 12:1079–1088PubMedGoogle Scholar
  52. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97(6):1634–1658 ReviewPubMedGoogle Scholar
  53. Hand R, Bortone D, Mattar P, Nguyen L, Heng JI, Guerrier S, Boutt E, Peters E, Barnes AP, Parras C, Schuurmans C, Guillemot F, Polleux F (2005) Phosphorylation of neurogenin2 specifies the migration properties and the dendritic morphology of pyramidal neurons in the neocortex. Neuron 48(1):45–62PubMedGoogle Scholar
  54. Henn FA, Vollmayr B (2004) Neurogenesis and depression: etiology or epiphenomenon? Biol. Psychiatry 56(3):146–150PubMedGoogle Scholar
  55. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A et al (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115(Pt 5):1249–1273PubMedGoogle Scholar
  56. Hibbeln JR (1998) Fish consumption and major depression. Lancet 351(9110):1213PubMedGoogle Scholar
  57. Hibbeln JR (2002) Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J. Affect. Disord. 69(1–3):15–29PubMedGoogle Scholar
  58. Horrobin DF (2001) Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase. Hum. Psychopharmacol. 16(1):45–52PubMedGoogle Scholar
  59. Huang SY, Yang HT, Chiu CC, Pariante CM, Su KP (2006) Omega-3 fatty acids on the forced-swimming test. J. Psychiatr. Res. 42(1):58–63PubMedGoogle Scholar
  60. Ishikawa I, Kitamura H, Kimura K, Saito M (2001) Brain interleukin-1 is involved in blood interleukin-6 response to immobilization stress in rats. Jap. J. Veterinary Res. 49(1):19–25Google Scholar
  61. Kawakita E, Hashimoto M, Shido O (2006) Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neurosci. 139(3):991–997Google Scholar
  62. Kempermann G, Neumann H (2003) Microglia: the enemy within? Science 302:1689–1690PubMedGoogle Scholar
  63. Kempermann G, Kuhn HG, Gage FH (1997) More hippocampal neurons in adult mice living in an enriched environment. Nature 386(6624):493–495PubMedGoogle Scholar
  64. Kenis G, Maes M (2002) Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5(4):401–412 ReviewPubMedGoogle Scholar
  65. Kent S, Bluthé RM, Kelley KW, Dantzer R (1992) Sickness behavior as a new target for drug development. Trends Pharmacol. Sci. 13(1):24–28PubMedGoogle Scholar
  66. Kerr SJ, Armati PJ, Guillemin GJ, Brew BJ (1998) Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12(4):355–363PubMedGoogle Scholar
  67. Khaspekov L, Kida E, Victorov I, Mossakowski MJ (1989) Neurotoxic effect induced by quinolinic acid in dissociated cell culture of mouse hippocampus. J. Neurosci. Res. 22(2):150–157PubMedGoogle Scholar
  68. Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, Steinbusch HW (2004) T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatr. Res. 129(3):267–272Google Scholar
  69. Kim YK, Jung HG, Myint AM, Kim H, Park SH (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 104(1–3):91–95PubMedGoogle Scholar
  70. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS. Medicine 5(2):e45PubMedGoogle Scholar
  71. Koo JW Duman RS (2008) IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Nat. Acad. Sci. USA 105:751–756Google Scholar
  72. Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, Claesson M (1996) Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol. J. Pharmacol. 48:503–506PubMedGoogle Scholar
  73. Kubera M, Van Bockstaele D, Maes M (1999) Leukocyte subsets in treatment-resistant major depression. Pol. J. Pharmacol. 51(6):547–549PubMedGoogle Scholar
  74. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M (2001a) Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J. Clin. Psychopharmacol. 21(2):199–206PubMedGoogle Scholar
  75. Kubera M, Maes M, Holan V, Basta-Kaim A, Roman A, Shani J (2001b) Prolonged desipramine treatment increases the production of interleukin-10, an anti-inflammatory cytokine, in C57BL/6 mice subjected to the chronic mild stress model of depression. J. Affect. Disord. 63(1–3):171–178PubMedGoogle Scholar
  76. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I (2005) Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 19(10):1347–1349PubMedGoogle Scholar
  77. Lacosta S, Merali Z, Anisman H (1999) Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic-like effects. Brain Res. 818(2):291–303PubMedGoogle Scholar
  78. Lapin IP (2003) Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety. Adv. Exp. Med. Biol. 527:121–125PubMedGoogle Scholar
  79. Lestage J, Verrier D, Palin K, Dantzer R (2002) The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav. Immun. 16(5):596–601PubMedGoogle Scholar
  80. Levivier M, Przedborski S (1998) Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. Neurol. Res. 20(1):46–56PubMedGoogle Scholar
  81. Lin A, Song C, Kenis G, Bosmans E, De Jongh R, Scharpe S, Maes M (2000) The in vitro immunosuppressive effects of moclobemide in healthy volunteers. J. Affect. Disord. 58(1):69–74PubMedGoogle Scholar
  82. Lin PY, Su KP (2007) A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatr. 68(7):1056–1061Google Scholar
  83. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, Souza DO, Portela LV, Gentil V (2007a) Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol. Psychiatry 61(2):142–144PubMedGoogle Scholar
  84. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V Jr, da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V (2007b) Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421(1):33–36PubMedGoogle Scholar
  85. Maes M (1993) A review on the acute phase response in major depression. Rev. Neurosci. 4(4):407–416 ReviewPubMedGoogle Scholar
  86. Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Progr. Neuropsychopharmacol. Biol. Psychiatry 19(1):11–38 ReviewGoogle Scholar
  87. Maes M (1999) Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 461:25–46 ReviewPubMedGoogle Scholar
  88. Maes M, Meltzer HY (1995) The Serotonin Hypothesis of major depression. Psychopharmacology, The Fourth Generation of Progress. In: Bloom F, Kupfer D (Ed) Raven Press, pp 933–944Google Scholar
  89. Maes M, Smith RS (1998) Fatty acids, cytokines, and major depression. Biol. Psychiatr. 43(5):313–314Google Scholar
  90. Maes M, De Ruyter M, Claes R, Bosma G, Suy E (1987) The cortisol responses to 5-hydroxytryptophan, orally, in depressive inpatients. J. Affect. Disord. 13(1):23–30PubMedGoogle Scholar
  91. Maes M, De Ruyter M, Claes R, Suy E (1988) Sex-related differences in the relationships between self-rated depression and biological markers. J. Affect. Disord. 15(2):119–125PubMedGoogle Scholar
  92. Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J (1990) Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiol. 24(3):115–120Google Scholar
  93. Maes M, De Meester I, Vanhoof G, Scharpe S, Bosmans E, Vandervorst C, Verkerk R, Minner B, Suy E, Raus J (1991) Decreased serum dipeptidyl peptidase IV activity in major depression. Biol. Psychiatry 30(6):577–586PubMedGoogle Scholar
  94. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E (1993a) Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am. J. Psychiatry 150(8):1189–1193PubMedGoogle Scholar
  95. Maes M, Meltzer HY, Scharpe S, Bosmans E, Suy E, De Meester I, Calabrese J, Cosyns P (1993b) Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatr. Res. 49(2):151–165Google Scholar
  96. Maes M, Meltzer HY, Scharpé S, Cooreman W, Uyttenbroeck W, Suy E, Vandervorst C, Calabrese J, Raus J, Cosyns P (1993c) Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatr. Res. 47(3):229–241Google Scholar
  97. Maes M, Scharpe S, Meltzer HY, Cosyns P (1993d) Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol. Psychiatry 34(10):690–701PubMedGoogle Scholar
  98. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J, Cosyns P (1993e) Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-drenal axis in severe depression. Psychiatr. Res. 49(1):11–27Google Scholar
  99. Maes M, Scharpe S, Meltzer H, Okayli G, D'Hondt P, Cosyns P (1994) Increased neopterin and interferon gamma secretion and lower L-tryptophan levels in major depression: further evidence for immune activation in severe depression. Psychiatr. Res. 54:143–160Google Scholar
  100. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995a) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatry Res. 29(2):141–152Google Scholar
  101. Maes M, Smith R, Scharpe S (1995b) The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinol. 20(2):111–116Google Scholar
  102. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H (1996a) Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J. Affect. Disord. 38(1):35–46PubMedGoogle Scholar
  103. Maes M, Wauters A, Verkerk R, Demedts P, Neels H, Van Gastel A, Cosyns P, Scharpe S, Desnyder R (1996b) Lower serum L-tryptophan availability in depression as a marker of a more generalized disorder in protein metabolism. Neuropsychopharmacol. 15(3):243–251Google Scholar
  104. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997a) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9(11):853–858PubMedGoogle Scholar
  105. Maes M, Calabrese J, Jayathilake K, Meltzer HY (1997b) Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatr. Res. 71(2):67–76Google Scholar
  106. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpe S (1997c) Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatr. Res. 66(1):1–11Google Scholar
  107. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyder R (1997d) Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol. Psychiatry 42(5):349–358PubMedGoogle Scholar
  108. Maes M, Song C, Lin A, De Jongh R, Van Gastel A, Kenis G, Bosmans E, De Meester I, Benoy I, Neels H, Demedts P, Janca A, Scharpe S, Smith RS (1998a) The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 10(4):313–318PubMedGoogle Scholar
  109. Maes M, Song C, Lin A, DeJong R, Van Gastel A, Kenis G, Bosmans E, DeMeester I, Neels H, Janca A, Scharpe S, Smith RS (1998b) Immune and clinical correlates of psychological stress-induced production of interferon-( and IL-10 in humans. In: Plotnikoff NP, Faith RE, Murgo AJ, Good RA (eds) Cytokines, Stress and Immunity, pp 39–50Google Scholar
  110. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY (1999a) Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatr. Res. 85(3):275–291Google Scholar
  111. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY (1999b) Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19(2):177–182PubMedGoogle Scholar
  112. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpe S (1999c) Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacol. 20(4):370–379Google Scholar
  113. Maes M, Song C, Lin AH, Pioli R, Kenis G, Kubera M, Bosmans E (1999d) In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacol. (Berl) 143(4):401–407Google Scholar
  114. Maes M, Van Bockstaele DR, Gastel A, Song C, Schotte C, Neels H, DeMeester I, Scharpe S, Janca A (1999e) The effects of psychological stress on leukocyte subset distribution in humans: evidence of immune activation. Neuropsychobiol. 39(1):1–9Google Scholar
  115. Maes M, Christophe A, Bosmans E, Lin A, Neels H (2000) In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biol. Psychiatr. 47(10):910–920Google Scholar
  116. Maes M, Capuron L, Ravaud A, Gualde N, Bosmans E, Egyed B, Dantzer R, Neveu PJ (2001a) Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacol. 24(2):130–140Google Scholar
  117. Maes M, Ombelet W, De Jongh R, Kenis G, Bosmans E (2001b) The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J. Affect. Disord. 63(1–3):85–92PubMedGoogle Scholar
  118. Maes M, Ombelet W, Verkerk R, Bosmans E, Scharpe S (2001c) Effects of pregnancy and delivery on the availability of plasma tryptophan to the brain: relationships to delivery-induced immune activation and early post-partum anxiety and depression. Psychol. Med. 31(5):847–858PubMedGoogle Scholar
  119. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpe S (2002) Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci. 71(16):1837–1848PubMedGoogle Scholar
  120. Maes M, Mihaylova I, Bosmans E (2007a) Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol. Lett. 28(4):456–462PubMedGoogle Scholar
  121. Maes M, Mihaylova I, DeRuyter MD, Kubera M, Bosmans E (2007b) The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression–and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol. Lett. 28(6):826–831PubMedGoogle Scholar
  122. Maes M, Mihaylova I, Kubera M, Bosmans E (2007c) Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol. Lett. 28(4):463–469PubMedGoogle Scholar
  123. Maes M, Mihaylova I, Leunis JC (2007d) Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. Neuro Endocrinol. Lett. 28(6):861–867PubMedGoogle Scholar
  124. Maes M, Mihaylova I, Ategis J-C (2008a) Evidence for an IgM-mediated immune response directed against nitro-bovine serum albumin (BSA) in chronic fatigue syndrome (CFS) and major depression (MDD): evidence that the immune response to nitrosative stress-induced damage of BSA is more pronounced in CFS than in MDD. Neuro Endocrinol. Lett. 2008, In pressGoogle Scholar
  125. Maes M, Kubera M, Leunis JC (2008b) The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol. Letters. 29(1):117–124Google Scholar
  126. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20(24):9104–9110PubMedGoogle Scholar
  127. Mamalakis G, Kalogeropoulos N, Andrikopoulos N, Hatzis C, Kromhout D, Moschandreas J, Kafatos A (2006) Depression and long chain n-3 fatty acids in adipose tissue in adults from Crete. Eur. J. Clin. Nutr. 60(7):882–888PubMedGoogle Scholar
  128. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L (2006) Mitochondrial dysfunction, oxidative stress and neurodegeneration. J. Alzheimer’s Dis. 10(1):59–73 ReviewGoogle Scholar
  129. Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, Wisniewski SR, Balasubramani GK, Trivedi MH, Rush AJ (2005) Gender differences in depression: findings from the STAR*D study. J. Affect. Disord. 87(2–3):141–150PubMedGoogle Scholar
  130. Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 1073–1074:25–37PubMedGoogle Scholar
  131. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP (2001) Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch. Neurol. 58(7):1081–1086PubMedGoogle Scholar
  132. Moncada S, Bolanos JP (2006) Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem. 97(6):1676–1689 ReviewPubMedGoogle Scholar
  133. Monje ML, Toda H, Palmer TD (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science 302:1760–1765PubMedGoogle Scholar
  134. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S, Parada LF, Nestler EJ (2007) Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol. Psychiatr. 61(2):187–197Google Scholar
  135. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatr. 11(7):680–684Google Scholar
  136. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. New Engl. J. Med. 344(13):961–966PubMedGoogle Scholar
  137. Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, Leonard BE (2007) Tryptophan breakdown pathway in bipolar mania. J. Affect. Disord. 102(1–3):65–72PubMedGoogle Scholar
  138. Ngai LY, Herbert J (2005) Glucocorticoid enhances the neurotoxic actions of quinolinic acid in the striatum in a cell-specific manner. J. Neuroendocrinol. 17(7):424–434PubMedGoogle Scholar
  139. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR, Maier SF (1998) Exposure to acute stress induces brain interleukin-1beta protein in the rat. J. Neurosci. 18:2239–2246PubMedGoogle Scholar
  140. Noraberg J, Poulsen FR, Blaabjerg M, Kristensen BW, Bonde C, Montero M, Meyer M, Gramsbergen JB, Zimmer J (2005) Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. Curr. Drug Targets. CNS Neurol. Disord. 4(4):435–452 ReviewPubMedGoogle Scholar
  141. Noraberg J, Jensen CV, Bonde C, Montero M, Nielsen JV, Jensen NA, Zimmer J (2007) Developmental expression of fluorescent proteins in organotypic hippocampal slice cultures from transgenic mice with example of excitotoxic neurodegeneration. ATLA. 35(1):61–70 ReviewPubMedGoogle Scholar
  142. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG (2007) Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41(3–4):326–331PubMedGoogle Scholar
  143. O'Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, Kelley KW, Dantzer R (2008) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry. [Epub ahead of print]Google Scholar
  144. Overstreet DH, Friedman E, Mathé AA, Yadid G (2005) The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci. Biobeh. Rev. 29(4–5):739–759Google Scholar
  145. Pariante CM, Miller AH (2001) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatr. 49(5):391–404Google Scholar
  146. Patel HC, Ross FM, Heenan LE, Davies RE, Rothwell NJ, Allan SM (2006) Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity. J. Neurosci. Res. 83(3):385–391PubMedGoogle Scholar
  147. Peet M, Murphy B, Shay J, Horrobin D (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol. Psychiatr. 43(5):315–319Google Scholar
  148. Pemberton LA, Kerr SJ, Smythe G, Brew BJ (1997) Quinolinic acid production by macrophages stimulated with IFNγ, TNF-alpha, and IFNα. J. Interf. Cytokine Res. 17(10):589–595CrossRefGoogle Scholar
  149. Periyasamy S, Sanchez ER (2002) Antagonism of glucocorticoid receptor transactivity and cell growth inhibition by transforming growth factor-beta through AP-1-mediated transcriptional repression. Int. J. Biochem. Cell Biol. 34(12):1571–1585PubMedGoogle Scholar
  150. Pettit JW, Lewinsohn PM, Joiner TE Jr (2006) Propagation of major depressive disorder: relationship between first episode symptoms and recurrence. Psychiatr. Res. 141(3):271–278Google Scholar
  151. Pláteník J, Stopka P, Vejrazka M, Stípek S (2001) Quinolinic acid-iron(ii) complexes: slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction. Free Radical Res. 34(5):445–459Google Scholar
  152. Polleux F, Ghosh A (2002) The slice overlay assay: a versatile tool to study the influence of extracellular signals on neuronal development. Science STKE 136(19):1–11Google Scholar
  153. Pong K (2003) Oxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimetics. Exp. Opin. Biol. Therap. 3(1):127–139 ReviewGoogle Scholar
  154. Post RM (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry 149(8):999–1010PubMedGoogle Scholar
  155. Post RM (2007) Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci. Biobehav. Rev 31(6):858–873PubMedGoogle Scholar
  156. Potashkin JA, Meredith GE (2006) The role of oxidative stress in the dysregulation of gene expression and protein metabolism in neurodegenerative disease. Antioxidant Redox Sign. 8(1–2):144–151 ReviewGoogle Scholar
  157. Qian L, Hong JS, Flood PM (2006) Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10. J. Neural Transm. Suppl. 70:367–371PubMedGoogle Scholar
  158. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55(5):453–462PubMedGoogle Scholar
  159. Rao JS, Lee HJ, Rapoport SI, Bazinet RP (2008) Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol. Psychiatr. 13(6):585–596Google Scholar
  160. Rios C, Santamaria A (1991) Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 16(10):1139–1143PubMedGoogle Scholar
  161. Sakic B, Szechtman H, Braciak T, Richards C, Gauldie J, Denburg JA (1997) Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6. Brain Res. Bull. 44(2):155–165PubMedGoogle Scholar
  162. Sakic B, Gauldie J, Denburg JA, Szechtman H (2001) Behavioral effects of infection with IL-6 adenovector. Brain Beh Immun. 15(1):25–42Google Scholar
  163. Sandi C (2004) Stress, cognitive impairment and cell adhesion molecules. Nature Reviews Neuroscience 5:917–930PubMedGoogle Scholar
  164. Sandi C, Bisaz R (2007) A model for the involvement of neural cell adhesion molecules in stress-related mood disorders. Neuroendocrinol. 85(3):158–176Google Scholar
  165. Sapolsky RM (2004) Is impaired neurogenesis relevant to the affective symptoms of depression? Biol. Psychiatry 56(3):137–139PubMedGoogle Scholar
  166. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S (2007) Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum. Psychopharmacol. 22(2):67–73PubMedGoogle Scholar
  167. Schiepers OJ, Wichers MC, Maes M (2005) Cytokines and major depression. Prog Neuropsychopharmacol. Biol. Psychiatr. 29(2):201–217Google Scholar
  168. Schmidt HD, Duman RS (2007) The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Beh. Pharmacol. 18(5–6):391–418Google Scholar
  169. Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A (2005) Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J. Neuroimmunol. 160(1–2):204–209PubMedGoogle Scholar
  170. Schwarcz R, Köhler C (1983) Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci. Lett. 38(1):85–90PubMedGoogle Scholar
  171. Shapira-Lichter I, Beilin B, Ofek K, Bessler H, Gruberger M, Shavit Y, Seror D, Grinevich G, Posner E, Reichenberg A, Soreq H, Yirmiya R (2008) Cytokines and cholinergic signals co-modulate surgical stress-induced changes in mood and memory. Brain Beh. Immun. 22:388–398Google Scholar
  172. Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J. Neurosci. 15:1768–1777PubMedGoogle Scholar
  173. Sobocki P, Jonsson B, Angst J, Rehnberg C (2006) Cost of depression in Europe. J. Ment. Health Policy Econ. 9(2):87–98PubMedGoogle Scholar
  174. Sobczak S, Honig A, Christophe A, Maes M, Helsdingen RW, De Vriese SA, Riedel WJ (2004) Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol. Med 34(1):103–112PubMedGoogle Scholar
  175. Song C, Leonard BE (1995) Interleukin-2-induced changes in behavioural, neurotransmitter, and immunological parameters in the olfactory bulbectomized rat. Neuroimmunomodulation. 2(5):263–273PubMedGoogle Scholar
  176. Song C, Leonard BE, Horrobin DF (2004) Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats. Stress 7(1):43–54PubMedCrossRefGoogle Scholar
  177. Song C, Li X, Kang Z, Kadotomi Y (2007) Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion. Neuropsychopharmacol. 32(3):736–744Google Scholar
  178. Steptoe A, Hamer M, Chida Y (2007) The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Beh. Immun. 21:901–912Google Scholar
  179. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HB, Friedman L, Rajkowska G (2004) Cellular changes in the postmortem hippocampus in major depression. Biol. Psychiatr. 56(9):640–650Google Scholar
  180. Stone TW, Behan WM (2007) Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. J. Neurosci. Res. 85(5):1077–1085PubMedGoogle Scholar
  181. Stork O, Welzl H, Wotjak CT, Hoyer D, Delling M, Cremer H, Schachner M (1999) Anxiety and increased 5-HT1A receptor response in NCAM null mutant mice. J. Neurobiol. 40:343–355PubMedGoogle Scholar
  182. Turner CA, Akil H, Watson SJ, Evans SJ (2006) The fibroblast growth factor system and mood disorders. Biol. Psychiatr. 59(12):1128–1135Google Scholar
  183. Ueda S, Sakakibara S, Yoshimoto K (2005) Effect of long-lasting serotonin depletion on environmental enrichment-induced neurogenesis in adult rat hippocampus and spatial learning. Neurosci. 135:395–402Google Scholar
  184. Vaidya VA, Duman RS (2001) Depression-emerging insights from neurobiology. Brit. Med. Bull. 57:61–79PubMedGoogle Scholar
  185. van Praag H, Kempermann G, Gage FH (1999) Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nature Neurosci. 2(3):266–270PubMedGoogle Scholar
  186. Viviani B, Gardoni F, Bartesaghi S, Corsini E, Facchi A, Galli CL, Di Luca M, Marinovich M (2006) Interleukin-1 beta released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors. J. Biol. Chem. 281(40):30212–3022PubMedGoogle Scholar
  187. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M (2002) Serological observations in patients suffering from acute manic episodes. Human Psychopharmacol. 17(4):175–179Google Scholar
  188. Walz JC, Frey BN, Andreazza AC, Cereser KM, Cacilhas AA, Valvassori SS, Quevedo J, Kapczinski F (2007) Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J. Psychiatr. Res. 42(5):416–421PubMedGoogle Scholar
  189. Wang JY, Wen LL, Huang YN, Chen YT, Ku MC (2006) Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr. Pharmac. Design 12(27):3521–3533 ReviewGoogle Scholar
  190. Wichers MC, Maes M (2004) The role of indoleamine 2, 3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J. Psychiatr. Neurosci. 29(1):11–17Google Scholar
  191. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M (2005) IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatr. 10(6):538–544Google Scholar
  192. Wichers MC, Kenis G, Koek GH, Robaeys G, Nicolson NA, Maes M (2007) Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J. Psychosom. Res. 62(2):207–214PubMedGoogle Scholar
  193. Wu A, Ying Z, Gomez-Pinilla F (2004) Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma. 21:1457–1467PubMedGoogle Scholar
  194. Xia Z, DePierre JW, Nassberger L (1996) Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacol. 34(1):27–37Google Scholar
  195. Xu Y, Ku B, Cui L, Li X, Barish PA, Foster TC, Ogle WO (2007) Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res. 1162:9–18PubMedGoogle Scholar
  196. Yang R, Han X, Uchiyama T, Watkins SK, Yaguchi A, Delude RL, Fink MP (2003) IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am. J. Physiol. Gastrointestinal Liver Physiol. 285(3):G621–629Google Scholar
  197. Yirmiya R (1996) Endotoxin produces a depressive-like episode in rats. Brain Res. 711(1–2):163–74PubMedGoogle Scholar
  198. Yirmiya R (1997) Behavioral and psychological effects of immune activation: implications for ‘depression due to a general medical condition’. Curr. Opin. Psychiatr. 10:470–476Google Scholar
  199. Yirmiya R, Weidenfeld J, Pollak Y, Morag M, Morag A, Avitsur R, Barak O, Reichenberg A, Cohen E, Shavit Y, Ovadia H (1999) Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv. Exp. Med. Biol. 461:283–316PubMedGoogle Scholar
  200. Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, Weihe E, Weidenfeld J (2001) Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacol. 24(5):531–544Google Scholar
  201. Zhu SW, Pham TM, Aberg E, Brene S, Winblad B, Mohammed AH, Baumans V (2006) Neurotrophin levels and behaviour in BALB/c mice: impact of intermittent exposure to individual housing and wheel running. Beh. Brain Res. 167(1):1–8Google Scholar
  202. Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res. 1034(1–2):11–24PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Michael Maes
    • 1
  • Raz Yirmyia
    • 2
  • Jens Noraberg
    • 3
    • 4
  • Stefan Brene
    • 5
  • Joe Hibbeln
    • 6
  • Giulia Perini
    • 7
  • Marta Kubera
    • 8
  • Petr Bob
    • 9
  • Bernard Lerer
    • 10
  • Mario Maj
    • 11
  1. 1.Clinical Research Center for Mental HealthAntwerp WilrijkBelgium
  2. 2.Department of PsychologyThe Hebrew UniversityJerusalemIsrael
  3. 3.Molecular Neurobiology Laboratory, Medical Biotechnology CenterUniversity of Southern DenmarkOdenseDenmark
  4. 4.Department of Anatomy and NeurobiologyUniversity of Southern DenmarkOdenseDenmark
  5. 5.Department of Neurobiology, Care Sciences and SocietyKarolinska University Hospital, MR CenterStockholmSweden
  6. 6.Section on Nutritional NeurochemistryLMBB, DICBR, NIAAA, NIHWashington DCUSA
  7. 7.Department of PsychiatryUniversity of PadovaPadovaItaly
  8. 8.Institute of PharmacologyPolish Academy of ScienceKrakowPoland
  9. 9.Psychiatric Department1st Medical Faculty Charles University in PraguePragueCzech Republic
  10. 10.Hadassah Biological Psychiatry LaboratoryHadassah-Hebrew UniversityJerusalemIsrael
  11. 11.Department of PsychiatryUniversity of Naples SUNNaplesItaly

Personalised recommendations